UGT1A1 and irinotecan: Ready for routine pharmacogenetic care

UGT1A1 glucuronidates irinotecan's active metabolite SN-38; reduced-function alleles increase toxicity risk.

This British Journal of Clinical Pharmacology editorial argues that UGT1A1 genotyping prior to irinotecan administration is now ready for routine pharmacogenetic care. The title advocates for systematic integration of this test into clinical practice to guide the management of patients treated with irinotecan. The detailed content of the editorial (data, arguments) is not available in the provided abstract.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

UGT1A1 genotyping before irinotecan is the subject of pharmacogenetic recommendations (DPWG, regulatory labeling) aimed at preventing severe hematologic and gastrointestinal toxicities in carriers of reduced-function alleles. An editorial favoring its generalization reflects the maturity of this gene-drug pair. Absent a detailed abstract, appraisal is limited to the position statement.

Analysis by Dr Thibaut Benquey